Quantitative comparison of the protein corona of nanoparticles with different matrices

Ottonelli, Ilaria; Duskey, Jason Thomas; Genovese, Filippo; Pederzoli, Francesca; Caraffi, Riccardo; Valenza, Marta; Tosi, Giovanni; Vandelli, Maria Angela; Ruozi, Barbara

doi:10.1016/j.ijpx.2022.100136

Cited by 3 publications

(4 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We optimized PLGA-based NMeds loaded with T3, which were fully characterized in terms of physico-chemical, morphological, and technological properties. Results showed that we obtained NMeds with a particle size near to 150 nm and a low PDI (<0.15), indicating a narrow size distribution and good homogeneity [49,50]. These properties, associated with the spherical shape of NMeds confirmed by the AFM and STEM investigations and with a strongly negative Z-potential [51], suggest that these NMeds are suitable for both storage and in vivo administration.…”

Section: Discussionmentioning

confidence: 65%

“…The second target of the "combo" therapy was inflammation. Inflammation after SCI is driven by a diverse set of cells and signaling molecules [50], leading to several detrimental effects such as tissue damage, increased vascular permeability, neuron, OPC, and OL apoptosis and cytotoxicity, lipid peroxidation, mitochondrial damage, etc. Moreover, the activity of THs on lesioned spinal cord tissue is severely hampered by inflammation, leading to tissue hypothyroidism and a condition known as "non thyroidal illness syndrome" [15,54].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

“Combo” Multi-Target Pharmacological Therapy and New Formulations to Reduce Inflammation and Improve Endogenous Remyelination in Traumatic Spinal Cord Injury

Moretti

Caraffi

Lorenzini

et al. 2023

Cells

Self Cite

View full text Add to dashboard Cite

Spinal cord injury (SCI) is characterized by a cascade of events that lead to sensory and motor disabilities. To date, this condition is irreversible, and no cure exists. To improve myelin repair and limit secondary degeneration, we developed a multitherapy based on nanomedicines (NMeds) loaded with the promyelinating agent triiodothyronine (T3), used in combination with systemic ibuprofen and mouse nerve growth factor (mNGF). Poly-L-lactic-co-glycolic acid (PLGA) NMeds were optimized and loaded with T3 to promote sustained release. In vitro experiments confirmed the efficacy of T3-NMeds to differentiate oligodendrocyte precursor cells. In vivo rat experiments were performed in contusion SCI to explore the NMed biodistribution and efficacy of combo drugs at short- and long-term post-lesion. A strong anti-inflammatory effect was observed in the short term with a reduction of type M1 microglia and glutamate levels, but with a subsequent increase of TREM2. In the long term, an improvement of myelination in NG2-IR, an increase in MBP content, and a reduction of the demyelination area were observed. These data demonstrated that NMeds can successfully be used to obtain more controlled local drug delivery and that this multiple treatment could be effective in improving the outcome of SCIs.

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

“Combo” Multi-Target Pharmacological Therapy and New Formulations to Reduce Inflammation and Improve Endogenous Remyelination in Traumatic Spinal Cord Injury

Moretti

Caraffi

Lorenzini

et al. 2023

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…The residual surfactant in the NP matrix was evaluated by an already published colorimetric method [ 53 , 54 ]. About 2 mg of NPs was solubilized in 0.5 mL of DCM and then added to 10 mL of water.…”

Section: Methodsmentioning

confidence: 99%

Optimization of an Injectable Hydrogel Depot System for the Controlled Release of Retinal-Targeted Hybrid Nanoparticles

et al. 2022

View full text Add to dashboard Cite

A drawback in the development of treatments that can reach the retina is the presence of barriers in the eye that restrain compounds from reaching the target. Intravitreal injections hold promise for retinal delivery, but the natural defenses in the vitreous can rapidly degrade or eliminate therapeutic molecules. Injectable hydrogel implants, which act as a reservoir, can allow for long-term drug delivery with a single injection into the eye, but still suffer due to the fast clearance of the released drugs when traversing the vitreous and random diffusion that leads to lower pharmaceutic efficacy. A combination with HA-covered nanoparticles, which can be released from the gel and more readily pass through the vitreous to increase the delivery of therapeutic agents to the retina, represents an advanced and elegant way to overcome some of the limitations in eye drug delivery. In this article, we developed hybrid PLGA-Dotap NPs that, due to their hyaluronic acid coating, can improve in vivo distribution throughout the vitreous and delivery to retinal cells. Moreover, a hydrogel implant was developed to act as a depot for the hybrid NPs to better control and slow their release. These results are a first step to improve the treatment of retinal diseases by protecting and transporting the therapeutic treatment across the vitreous and to improve treatment options by creating a depot system for long-term treatments.

show abstract

“…The PC environment can be manipulated by attaching various stealth-inducing biological materials like alginic acid or hyaluronic acid to the NPs. Such attachments alter the sizes, surface potentials, and stabilities of the NPs [202].…”

Section: Lipid-based Nanoparticles (Lnps)mentioning

confidence: 99%

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology

Chaudhuri

Kumar

Deepa

et al. 2023

Cancers

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease which accounts globally for approximately 1 million new cases annually, wherein more than 200,000 of these cases turn out to be cases of triple-negative breast cancer (TNBC). TNBC is an aggressive and rare breast cancer subtype that accounts for 10–15% of all breast cancer cases. Chemotherapy remains the only therapy regimen against TNBC. However, the emergence of innate or acquired chemoresistance has hindered the chemotherapy used to treat TNBC. The data obtained from molecular technologies have recognized TNBC with various gene profiling and mutation settings that have helped establish and develop targeted therapies. New therapeutic strategies based on the targeted delivery of therapeutics have relied on the application of biomarkers derived from the molecular profiling of TNBC patients. Several biomarkers have been found that are targets for the precision therapy in TNBC, such as EGFR, VGFR, TP53, interleukins, insulin-like growth factor binding proteins, c-MET, androgen receptor, BRCA1, glucocorticoid, PTEN, ALDH1, etc. This review discusses the various candidate biomarkers identified in the treatment of TNBC along with the evidence supporting their use. It was established that nanoparticles had been considered a multifunctional system for delivering therapeutics to target sites with increased precision. Here, we also discuss the role of biomarkers in nanotechnology translation in TNBC therapy and management.

show abstract

Quantitative comparison of the protein corona of nanoparticles with different matrices

Cited by 3 publications

References 139 publications

“Combo” Multi-Target Pharmacological Therapy and New Formulations to Reduce Inflammation and Improve Endogenous Remyelination in Traumatic Spinal Cord Injury

“Combo” Multi-Target Pharmacological Therapy and New Formulations to Reduce Inflammation and Improve Endogenous Remyelination in Traumatic Spinal Cord Injury

Optimization of an Injectable Hydrogel Depot System for the Controlled Release of Retinal-Targeted Hybrid Nanoparticles

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology

Contact Info

Product

Resources

About